Home
/
Zentalis Pharmaceuticals, Inc.
/
Financials
/
Quarterly
Zentalis Pharmaceuticals, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Zentalis Pharmaceuticals, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$0
Nov 10, 2025
Q2
2025
Jun 30, 2025
$0
Aug 6, 2025
Q1
2025
Mar 31, 2025
$0
May 14, 2025
Q3
2025
Sep 30, 2024
$0
Nov 10, 2025
Q2
2025
Jun 30, 2024
$0
Aug 6, 2025
Q1
2025
Mar 31, 2024
$40.56M
May 14, 2025
Q3
2024
Sep 30, 2023
$0
Nov 12, 2024
Q2
2024
Jun 30, 2023
$0
Aug 9, 2024
Q1
2024
Mar 31, 2023
$0
May 7, 2024
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($26.69M)
Nov 10, 2025
Q2
2025
Jun 30, 2025
($26.87M)
Aug 6, 2025
Q1
2025
Mar 31, 2025
($48.28M)
May 14, 2025
Q3
2025
Sep 30, 2024
($40.16M)
Nov 10, 2025
Q2
2025
Jun 30, 2024
($88.28M)
Aug 6, 2025
Q1
2025
Mar 31, 2024
$10.07M
May 14, 2025
Q3
2024
Sep 30, 2023
($55.53M)
Nov 12, 2024
Q2
2024
Jun 30, 2023
($112.53M)
Aug 9, 2024
Q1
2024
Mar 31, 2023
($63.22M)
May 7, 2024
Q3
2023
Sep 30, 2022
($54.40M)
Nov 6, 2023
Q2
2023
Jun 30, 2022
($68.36M)
Aug 9, 2023
Q1
2023
Mar 31, 2022
($59.08M)
May 10, 2023
Q3
2022
Sep 30, 2021
($4.19M)
Nov 9, 2022
Q2
2022
Jun 30, 2021
($54.57M)
Aug 9, 2022
Q1
2022
Mar 31, 2021
($49.90M)
May 5, 2022
Q3
2021
Sep 30, 2020
($34.56M)
Nov 10, 2021
Q2
2021
Jun 30, 2020
($26.86M)
Aug 12, 2021
Q1
2021
Mar 31, 2020
($16.13M)
May 17, 2021
Q3
2020
Sep 30, 2019
($12.34M)
Nov 9, 2020
Q2
2020
Jun 30, 2019
($10.47M)
Aug 13, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($33.73M)
Nov 10, 2025
Q2
2025
Jun 30, 2025
($36.06M)
Aug 6, 2025
Q1
2025
Mar 31, 2025
($45.62M)
May 14, 2025
Q3
2025
Sep 30, 2024
($51.43M)
Nov 10, 2025
Q2
2025
Jun 30, 2024
($65.15M)
Aug 6, 2025
Q1
2025
Mar 31, 2024
($24.77M)
May 14, 2025
Q3
2024
Sep 30, 2023
($62.72M)
Nov 12, 2024
Q2
2024
Jun 30, 2023
($103.92M)
Aug 9, 2024
Q1
2024
Mar 31, 2023
($64.95M)
May 7, 2024
Q3
2023
Sep 30, 2022
($54.19M)
Nov 6, 2023
Q2
2023
Jun 30, 2022
($63.46M)
Aug 9, 2023
Q1
2023
Mar 31, 2022
($57.88M)
May 10, 2023
Q3
2022
Sep 30, 2021
($62.87M)
Nov 9, 2022
Q2
2022
Jun 30, 2021
($55.13M)
Aug 9, 2022
Q1
2022
Mar 31, 2021
($50.35M)
May 5, 2022
Q3
2021
Sep 30, 2020
($34.77M)
Nov 10, 2021
Q2
2021
Jun 30, 2020
($27.38M)
Aug 12, 2021
Q1
2021
Mar 31, 2020
($16.40M)
May 17, 2021
Q3
2020
Sep 30, 2019
($12.58M)
Nov 9, 2020
Q2
2020
Jun 30, 2019
($10.64M)
Aug 13, 2020